Speakers:
Jessica Williams, MD, FAAP, D-ABOM has no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.
Jessica Williams, MD, FAAP, D-ABOM has indicated the presentation may include discussion of any off-label uses of a product.
Explanation Given: medications for pediatric obesity often include off label choices: metformin, lisdexamfetamine, phentermine monotherapy, topamax monotherapy
Connecticut Children’s is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Connecticut Children's designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only credits commensurate with the extent of their participation in the various activities. • MOC Part 2: Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to 1 MOC points in the American Board of Pediatrics’ (ABP) and the American Board of Surgery’s (ABS) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit. Conflict of Interest Policy: All faculty participating in Continuing Medical Education activities sponsored by Connecticut Children’s are required to disclose to the program audience any actual or perceived conflict of interest related to the content of their presentation. Program planners have an obligation to resolve any actual conflicts of interest and share with the audience any safeguards put in place to prevent commercial bias from influencing the content. The additional planners, activity director and speaker(s) do not have a financial interest/arrangement or affiliation with any organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation. All relevant financial relationships have been mitigated according to the ACCME guidelines. Jessica Williams, MD, FAAP, D-ABOM has indicated the presentation may include discussion of any off-label uses of a product. Explanation Given: medications for pediatric obesity often include off label choices: metformin, lisdexamfetamine, phentermine monotherapy, and topamax monotherapy